Kidney cancer drug data update shows improvement, Kura stock rises

Previously, the company released preliminary subgroup analysis data on the combination treatment of darlifarnib and cabozantinib for patients with clear cell renal cell carcinoma (ccRCC) who had previously been treated with cabozantinib. According to a statement, the relevant results are from the ongoing FIT-001 clinical trial: Subgroup analysis data on patients previously treated with cabozantinib supported the potential of this therapy to overcome resistance. Tumor reduction was observed in 75% of patients. Across multiple dose levels, all renal cell carcinoma (RCC) patients demonstrated manageable safety and tolerability characteristics.